International AIDS Vaccine Initiative

What it reported doing in 2025

Research and development: through scientific and clinical research in africa, india, europe, and the u.s., iavi develops vaccines and antibodies in and for the developing world and seeks to accelerate their introduction in low-income countries. Iavi advances scientific discovery and development by fostering unique collaborations among academia, industry, local communities, governments, and funders to explore new and better ways to address public health threats that disproportionately affect people living in poverty. Vaccine and antibody candidates are put through a rigorous process of clinical evaluation among key populations to establish their safety and efficacy, an effort that enables iavi to strengthen the healthcare infrastructure and scientific ( see schedule o for continuation) capacity of countries where our clinical partners operate. To date, iavi and its partners have advanced dozens of HIV vaccine candidates into early stage clinical trials, including a vaccine candidate that has yielded promising early results and is part of an exciting new approach to HIV vaccine design. Other notable achievements include the first HIV vaccine trials in sub-saharan countries, where HIV burden is greatest, and the first trial of an mrna HIV vaccine candidate in africa. Iavi has conducted more than 50 epidemiological studies and provided voluntary HIV testing, counseling services, and health care referrals to more than 870,000 individuals in africa. Iavi also supports preclinical development and clinical testing of vaccine candidates for other diseases, including tuberculosis, lassa fever, and marburg, sudan, and bundibugyo virus diseases, as well as antibody candidates for disease prevention and treatment. Iavi conducts trials with the highest scientific and ethical standards to protect the rights, well-being, and dignity of trial volunteers. Iavi has also launched research consortia to address major scientific problems of biomedical product development. A significant portion of the research iavi supports is conducted in low-income countries where the need for infectious disease prevention is greatest.iavi also supports external researchers by providing technical and scientific expertise to accelerate the development of their own products.

Financial Efficiency

• Mission deployment rate: 88.8%; rating input score 89
• Program expense ratio: 85.2%; rating input score 85
• Fundraising efficiency: $590.76 raised per $1 spent on fundraising; rating input score 94; 94th percentile among comparable filings

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 66th percentile among comparable filings
• Pay-setting controls: 4 of 6 controls in place; rating input score 67
  • Compensation committee: Pass
  • Independent consultant: Missing
  • Other Form 990s reviewed: Pass
  • Written employment contract: Missing
  • Compensation survey or study: Pass
  • Board or committee approval: Pass
• Foreign activity oversight: 1 of 8 controls in place; rating input score 12
  • Claims monitoring procedures: Pass
  • Requires narrative reports: Limited
  • Conducts field audits: Limited
  • May suspend future funding: Limited
  • Requires financial reports: Limited
  • Conducts site visits: Limited
  • Requires grant agreements: Limited
  • May require repayment: Limited
• Grant itemization coverage: 100%; rating input score 100; 61st percentile among comparable filings
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Yes; rating input score 100

Accountability

• Independent voting board: 92.9%; rating input score 93; 24th percentile among comparable filings
• Governance controls: 9 of 9 controls in place; rating input score 100
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: Pass
  • Other executive compensation review process: Pass
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Pass
  • Independent financial-statement audit: Pass

Sustainability

• Operating margin: -3.8%; rating input score 8; 8th percentile among comparable filings
• Total-asset coverage ratio: 1.31; rating input score 36; 36th percentile among comparable filings
• Liabilities to assets ratio: 0.65; rating input score 26; 26th percentile among comparable filings
• Officer compensation ratio: 4.1%; rating input score 29; 29th percentile among comparable filings

Growth

• Program expense growth: 7% per year; rating input score 100; 53rd percentile among comparable filings
• Revenue growth: 6.1% per year; rating input score 100; 51st percentile among comparable filings
• Asset growth: 2% per year; rating input score 100; 11th percentile among comparable filings